UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

An unexplained weight loss happens when you lose a significant amount of weight without a change in diet, exercise, or lifestyle. There seems no reason for it, which is why it's sometimes called ...

Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones. “The general denominator of empagliflozin therapy was the dramatic increase in ...

People with diabetes should eat as much protein as people who don't have diabetes. In a healthy diet, roughly 10% to 35% of your daily calories should come from protein. Protein itself does not have ...

Menopause is associated with an increased risk of osteoporosis and coronary artery disease. The onset of menopause is an excellent time to assess a woman's overall health and the need for hormone ...

This case report presents a 57-year-old male with hepatocellular carcinoma who developed Type 1 Diabetes Mellitus (T1DM) and diabetic ketoacidosis (DKA) following treatment with Envafolimab, a PD-L1 ...

ABSTRACT: Introduction: Diabetic ketoacidosis (DKA) is the most common metabolic complication of diabetes. Although historically reported in children, it is increasingly observed in adults. Short-term ...

Severe ADRs were reported in empagliflozin, such as ketoacidosis and infections ... angiotensin II type 1 receptor; SGLT2, sodium-glucose co-transporter 2; GLUT1, glucose transporter type 1. Overall ...

while dapagliflozin was associated with a lower risk of diabetic ketoacidosis. To TCTMD, Wiviott said there is a large body of evidence supporting the SGLT2 inhibitor drug class, noting the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Comparative ...